EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.

(2017) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY

Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials

(2014) Lorna A Fern et al.   LANCET ONCOLOGY

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials

(2011) J. S. Whelan et al.   ANNALS OF ONCOLOGY

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

(2011) Anne McTiernan et al.   EUROPEAN JOURNAL OF CANCER

Incidence and survival of malignant bone sarcomas in England 1979-2007

(2011) Jeremy Whelan et al.   INTERNATIONAL JOURNAL OF CANCER

Osteosarcoma: Time to move on?

(2010) Stefan S. Bielack   EUROPEAN JOURNAL OF CANCER

The role of interferons in the treatment of osteosarcoma

(2009) Jeremy Whelan et al.   PEDIATRIC BLOOD & CANCER

Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group

(2008) L Fern et al.   BRITISH JOURNAL OF CANCER